

INSTITUTIONAL REVIEW BOARD APPLICATION for Exempt, Expedited and Full Board Studies

OFFICE USE ONLY		
DATE RECEIVED	REVIEW TYPE (CHECK ONE)	
//	EXEMPT EXPEDITED FULL REVIEW	
RECEIVED BY LAST NAME	RECEIVED BY FIRST NAME	
ACCEPTED REJECTED	VICE PRESIDENT'S SIGNATURE	DATE
		//
ADDITIONAL ADMINISTRATIVE SI	GNATURE	DATE
		//
IRB COMMITTEE DATE RECEIVED		
//		
ACCEPTED REJECTED	SIGNATURE	
	SIGNATURE	
ACCEPTED REJECTED		
ACCEPTED REJECTED	SIGNATURE	
ACCEPTED REJECTED	SIGNATURE	
ACCEPTED REJECTED	SIGNATURE	

PROJECT INFORMATION

PROJECT TITLE	
APPLICATION TYPE INITIAL APPLICATION	

PLEASE NOTE THAT HANDWRITTEN AND OR INCOMPLETE FORMS WILL NOT BE ACCEPTED.

PART I - INVESTIGATOR AND KEY RESEARCH PERSONNEL

Principal Investigator

LAST NAME		FIRST NAME			TITLE DR. D	MR. 🔲 MS.
INVESTIGATOR STA	TUS		DAYTIME TE	ELEPHONE		
FACULTY	GRADUATE STUDENT	STAFF	()		
E-MAIL ADDRESS						
COLLEGE/DEPARTM	IENT					
CAMPUS ADDRESS		CITY			STATE	ZIP CODE
MAILING ADDRESS		CITY			STATE	ZIP CODE

Principal Investigator *Continued*

State the research activities which this person will be involved in and whether formal training has been received (i.e., acquiring consent, recruiting, data monitoring, administering questionnaires, etc.):

What is the anticipated amount of time this individual will spend on this project?

Faculty Sponsor (If Applicable)

LAST NAME	FIRST NAME		TITLE DR. D M	IR. 🔲 MS.
INVESTIGATOR STATUS	- -	DAYTIME TELEPHONE	0-	
GRADUATE STUDENT ST	AFF OTHER	()		
E-MAIL ADDRESS				
COLLEGE/DEPARTMENT				
CAMPUS ADDRESS	CITY		STATE	ZIP CODE
MAILING ADDRESS	CITY		STATE	ZIP CODE

State the research activities which this person will be involved in and whether formal training has been received (i.e., acquiring consent, recruiting, data monitoring, administering questionnaires, etc.):

What is the anticipated amount of time this individual will spend on this project?

Co-Investigator (If Applicable)

LAST NAME	FIRST NAME			TITLE \square DR. \square M	IR. 🗖 MS.
INVESTIGATOR STATUS GALLTY GRAUNDERGRADUATE STUDENT STAFF		DAYTIME TE	ELEPHONE)		
E-MAIL ADDRESS					
COLLEGE/DEPARTMENT					
CAMPUS ADDRESS	CITY			STATE	ZIP CODE
MAILING ADDRESS	CITY			STATE	ZIP CODE

Co-Investigator (If Applicable) Continued

State the research activities which this person will be involved in and whether formal training has been received (i.e., acquiring consent, recruiting, data monitoring, administering questionnaires, etc.):

What is the anticipated amount of time this individual will spend on this project?

PART II - FUNDING INFORMATION

Check all of the appropriate boxes for funding sources for this research. Include pending funding source(s).				
P.I. OF GRANT/CONTRACT LAST NAME	P.I. OF GRANT/CONTRACT FIRST NAME			
SPONSOR LAST NAME	SPONSOR FIRST NAME			
GRANT/CONTRACT NUMBER (IF APPLICABLE)				
GRANT/CONTRACT TITLE				

You must submit all necessary documentation regarding research and grant proposals.

PART III - RESEARCH BACKGROUND

START DATE		END DATE		
//		//		
Will the research result in any of the following? (Check all that apply.)				
THESIS DISSERTATION PUL	BLISHED RESEARCH			
MAXIMUM NUMBER OF PARTICIPANTS PARTICIPANT MINIMU		UM AGE	PARTICIPANT MAXIMUM AGE	
GENDER		LOCATION OF RESEARCH	RECRUITMENT	
MALES FEMALES				
CRITERIA FOR PARTICIPANT SELECTION				
CRITERIA FOR NONSELECTION OR EXCLUSION	(IF NONE, ENTER "NON	IE.")		

Methods of Enrollment

 Indicate method(s) for finding potential participants. (Check all that apply and attach copies of recruitment materials.)

 CLASSROOM RECRUITMENT
 NO. OF PARTICIPANTS EXPECTED FROM THIS METHOD:

 ADVERTISEMENT
 NO. OF PARTICIPANTS EXPECTED FROM THIS METHOD:

 WEB LISTING/E-MAIL
 NO. OF PARTICIPANTS EXPECTED FROM THIS METHOD:

 OTHER (PLEASE DESCRIBE.)
 NO. OF PARTICIPANTS EXPECTED FROM THIS METHOD:

Methods of Enrollment Continued

How will potential participants be approached? (Check all that apply.)
Will medical clearance or a medical screening be necessary for subjects to participate because of the administration of food or physical exercise conditioning?
If yes, explain below how clearance will be obtained. If a screening instrument will be used, please attach a copy to the application.
SPECIAL POPULATIONS (i.e., POTENTIAL RISK CATEGORIES) CHILDREN (UNDER 18 YEARS OF AGE) PREGNANT WOMEN COGNITIVELY IMPAIRED INCARCERATED INDIVIDUALS (ADULT OR JUVENILE) STUDENTS ENROLLED IN A CLASS IN WHICH THE INSTRUCTOR IS THE INVESTIGATOR
Is the use of existing data archival record? \Box yes \Box NO
Is the use of existing data publicly available? ("Publicly available" means that the information is accessible to anyone without any fees or authorizations.) \Box YES \Box NO
Describe how you will gain access to data and any confidentiality processes used to protect participant identity.
<u>Project Abstract</u> : Provide a brief summary, 100 words or less, of the project abstract. Include the purpose/ hypothesis, experimental design, proposed procedure and importance of knowledge reasonably expected to result from the research. If the research involves more than minimal risk, describe the research plan for monitoring the data collected to ensure the safety of participants.

Level of Review

Are you requesting Exempt Status? (Please refer	to IRB document on description of Exempt Status.)			
Are you requesting Expedited Status? YES NO				
PART IV - PRIVACY AND CONFIDENTIALI	TY PROCEDURES			
Will audio data be recorded? YES NO	Will video data be recorded? U YES NO			
Will photographs be taken? U YES NO				

Please describe methods for preserving confidentiality. How will data be recorded and scored — with or without identifiers? If identifiers are used, describe the type (names, job titles, number code, etc.). How will reports be written — in aggregate terms or will individual responses be described? Will subjects be identified in reports? Describe disposition of materials at the end of the study. Describe any future use of materials.

PART V - INFORMED CONSENT INFORMATION

Informed Consent: Please attach, as an appendix, an informed consent document to this application. If subject participation is not anonymous, you must attach a consent form to this application. (Please attach your participation and permission forms for parents/legal guardians or consent forms for adult participation.)			
Who will be consenting to participate in the research?			
PARTICIPANT (MUST BE 18 OR OLDER)	LDREN (BELOW 18 YEARS)		
GUARDIAN LEGALLY AUTHOR	RIZED REPRESENTATIVE		
Is the primary language of the consent process English	? 🗖 yes 🗖 no		
If No:			
1. State other language(s) and indicate who will provide	de verbal and written translation services:		
LANGUAGE(S)			
LAST NAME	FIRST NAME		
2. Submit appropriately translated consent document(s) following IRB ESL mandates, prior to consenting non-		
English speaking participants.			

Waiver of Consent Process

In requesting a waiver of consent, explain below how this research involves no more than minimal risk to the subject. Loss of confidentiality is, under most circumstances, more than minimal risk. However, contact by primary care givers or others who by the nature of their involvement with the subject already have access to the data, will be considered no further loss of confidentiality and, therefore, may be less of a risk to subject confidentiality. Risk may also vary with the type of information being collected.

confidentiality. Kisk may also vary with the type of information being confected.
Is a waiver of the consent process requested? \Box YES \Box NO
If yes, explain the reason for the waiver:

Waiver of Signed Written Consent

Participants will not be required to sign a consent document when a waiver of signed written consent is reviewed and approved by the IRB. If the IRB waives the requirement of documentation of informed consent, the IRB may require the investigator to provide a written statement of the research to the participant. The IRB shall review and approve the written statement prior to the investigator providing the statement to the participant. The consent form reviewed and approved by the IRB may also serve as the written statement.

Is a waiver of signed written consent requested? \Box yes \Box NO

If yes:	
1. Ex	plain the reason for the waiver:
2. Se	lect either Category 1 or Category 2 below:
	Category 1: The only record linking the participant and the research is the consent document and the principal risk would be potential harm resulting from a breach of confidentiality. Each participant will be asked whether he or she wants documentation linking him or her with the research and his or her wishes will govern. The research is not subject to FDA regulations. Explain:
	Category 2: The research presents no more than minimal risk of harm to participants and involves no procedures for which written consent is normally required outside of the research context. Explain:

PART VI - RISKS AND BENEFITS

1.]	Does the research involve any of the following possible risks or harms to subjects? Check all that apply: Use of deception*
	(*If deception is used, please describe below. Also describe the debriefing process and include the debriefing script. In addition, the principal investigator should offer the participant the opportunity to withdraw his or her data after learning that deception was used in the study. Please include this information in the debriefing script submitted to the IRB.
	Use of confidential records (e.g., educational or medical records) Manipulation of psychological or social variables such as sensory deprivation, social isolation, psychological stressors, etc.
	Any probing for personal or sensitive information in surveys or interviews Presentation of materials that subjects might consider sensitive, offensive, threatening or degrading Invasion of privacy of subject or family
	Social or economic risk Risk associated with exercise or physical exertion
	Legal risk Employment/occupational risk
	Other risks
	Explain other risks:
	l any record of the subject's participation in this study be made available to his or her supervisor, teacher or bloyer? \Box YES \Box NO
	es, explain:
	Describe the nature and degree of all risk and or harm associated with participation in the study, including se checked in the previous section. If none, state "None."
rese	Explain what steps will be taken to minimize risk and or harm and to protect participant welfare. If the earch will include special populations, please identify each group and answer this question for each group. line steps to be taken to address confidentiality for all participants.

4.	Describe the anticipated	benefits of	of this	research	for the	e individual	participants	in eac	h subject	group.	If
no	ne, state "None."										

5. Describe the anticipated benefits of this research for society and explain how the benefits outweigh the risks.

PART VII - COMPENSATION INFORMATION

Will any compensation be offered to the participants for their participation? \Box YES \Box NO

(Please Note: Course credit cannot be a contingent factor for participation in the research. Participants may also reserve the right to withdraw from the research at any time without penalty.)

If yes, describe these inducements below and include a statement in the informed consent document explaining how compensation will be handled in the event the participant withdraws from the study.

PRINCIPAL INVESTIGATOR/FACULTY SPONSOR ASSURANCE

I certify that the information provided in this application is complete and correct.

I understand that as Principal Investigator, I have the responsibility for the conduct of the study, the ethical performance of the project and protection of the rights and welfare of human participants.

I agree to comply and assure that all affiliated personnel comply with all HSSU policies and procedures, as well as with all applicable federal, state and local laws regarding the protection of human participants in research.

I assure that this study is performed by qualified personnel adhering to the HSSU IRB approved protocol.

I assure that no modification to the approved protocol and consent materials will be made without first submitting it for review and approval by the HSSU IRB as an amendment to the approved protocol.

I agree to obtain legally effective informed consent from the research participants as applicable to this research and as prescribed in the approved protocol.

I will promptly report unanticipated problems to the HSSU IRB by using the appropriate form.

I will adhere to all requirements for continuing review.

I will advise the HSSU IRB of any change of address or contact information as long as this protocol remains active.

I assure that I have obtained all necessary approvals from entities other than the HSSU IRB that are necessary to conduct this research.

By my signature on this research application, I certify that I am knowledgeable about the regulations and policies governing research with human subjects and have sufficient training and experience to conduct this particular study in accordance with the research protocol.

Principal Investigator

PRINT LAST NAME	PRINT FIRST NAME			
SIGNATURE		DATE //		

Faculty Sponsor

PRINT LAST NAME	PRINT FIRST NAME	
SIGNATURE	I	DATE/

Co-Investigator

PRINT LAST NAME	PRINT FIRST NAME	
SIGNATURE		DATE
		//

For More Information and Application Submission, contact:

Dr. Dwyane Smith HSSU IRB Committee Chairman 3026 Laclede Avenue, Room 106; St. Louis, MO 63103 Phone: (314) 340-3612 Fax: (314) 340-3398 <u>SmithD@hssu.edu</u>

Revised February 10, 2010.